Targets › TGFBR2
7 programs from 3 companies in 11 trials: 10 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.
Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells,…. (UniProt, P37173)
Open in Phaseline: the race on TGFBR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical | TQB2868 injection Anti-PD-1/TGF-βRII bifunctional fusion protein | PDCD1, TGFBR2 | Phase 2 | Pancreatic Neoplasms | Nov 2026 |
| M.D. Anderson Cancer Center | CB-NK-TGF-betaR2-/NR3C1- Cord blood-derived engineered natural killer cells with deleted TGF-betaR2 and NR3C1 (gluc | TGFBR2, NR3C1 | Phase 1 | Recurrent Gliosarcoma | Jan 2027 |
| M.D. Anderson Cancer Center | Cytokine-treated Veto Cells CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel | IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2 | Phase 1 | Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal Cancer | Dec 2027 |
| M.D. Anderson Cancer Center | TROP2 CAR/IL-15 TGFBR2 KO NK cells CAR-T cell therapy targeting TROP2 with IL-15 transduction and TGFBR2 knockout in cord blo | TROP2, IL15, TGFBR2 | Phase 1 | Head and Neck Cancer | Dec 2027 |
| M.D. Anderson Cancer Center | TGFBR2 KO CAR27/IL-15 NK cells TGFBR2 knock-out cord blood-derived NK cells transduced with IL-15 and engineered with CAR | TGFBR2, IL15 | Phase 1 | Myeloid Malignancies | May 2028 |
| M.D. Anderson Cancer Center | TGFBR2 KO CAR27/IL-15 NK cells TROP2-targeted CAR-NK cells with IL-15 co-expression and TGFBR2 knockout | TROP2, TGFBR2, IL15 | Phase 1 | Gastric Cancer, Metastatic; Lymphoid | Jul 2028 |
| University of Chicago | NY-ESO-1 TCR/ dnTGFβRII Gene-modified T cells expressing NY-ESO-1-specific T cell receptor and dominant-negative T | TRA, TRB, TGFBR2 | Phase 1 | Ovarian Cancer | Dec 2031 |
Gastric Cancer, Metastatic (1) Lymphoid (1) Myeloid Malignancies (1) Ovarian Cancer (1) Pancreatic Neoplasms (1) Acute Lymphoblastic Leukemia (1) Acute Myeloid Leukemia (1) Phase 1 (1) Colorectal Cancer (1) Head and Neck Cancer (1) Recurrent Gliosarcoma (1)
mixed (5), small molecule (1), other (1)
M.D. Anderson Cancer Center (5) University of Chicago (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1)
TROP2 (3) IL15 (3) NR3C1 (2) TRA (1) TRB (1) PDCD1 (1) IL13RA1 (1) EGFR (1) IL21 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.